HUDDINGE, Sweden, May 21, 2003 (PRIMEZONE) -- Medivir will host a teleconference on 21 May at 11:00 SE time. Lars Adlersson CEO, Johan Harmenberg VP Pharmaceutical Development and Rein Piir CFO/IR, will present and comment on the GlaxoSmithKline licensing agreement.
To participate please dial +44 (0) 207 162 0179, code Medivir. The teleconference will be recorded and saved for 5 days. To reach the recorded version please dial +44 (0) 208 288 4459 and use code 651 442 from 13:00 SE time.
The Medivir Group
Medivir is an innovative, specialist research corporation that produces and develops pharmaceuticals. The company is located in Huddinge, Sweden and Cambridge, UK. Medivir's research is focused on developing new drug compounds based on proteases and polymerases as target enzymes.
The group comprises Medivir AB, the subsidiaries Medivir UK Ltd. and CCS AB, plus second-tier subsidiaries CCS (UK) Ltd. and Nordic Care Sweden AB. CCS develops, manufactures and markets skin-care products and pharmaceuticals. Medivir has been quoted on the Stockholm Stock Exchange since 1996.
Medivir's research portfolio includes projects against HIV, jaundice, shingles, cold sores, osteoporosis, RA (rheumatoid arthritis), asthma and MS (multiple sclerosis).
Medivir has four projects in clinical development phases, two of which are entering phase III after completing phase II. One project is in phase I and one is in phase II.
In the first stage of preclinical pharmaceutical discovery, Medivir has some ten activities in explorative activities; the second, lead identification, encompasses three projects. The third stage, optimization, has one project, and two projects entering this phase. One project-MV026048-is in preclinical development, the stage closest to clinical development.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2003/05/21/20030520BIT00990/wkr0001.doc
http://www.waymaker.net/bitonline/2003/05/21/20030520BIT00990/wkr0002.pdf